Skip to content

Idexx Laboratories Inc

Idexx Laboratories

IDXX · NASDAQ

Healthcare

Catalog as of September 15, 2026. Not a live market feed.

Fiscal Year
2025
Revenue
$4.3B
Assets
$3.4B
SEC filing
DEF 14A
Filed
March 27, 2026

Executive Compensation

Compensation reported for Idexx Laboratories’ named executive officers, including salary, stock awards, incentive compensation, other compensation, and total compensation.

Jonathan J. Mazelsky

President And Chief Executive Officer

$14.6M

Reported total · FY2025 · SCT Total as filed

Source: DEF 14A Summary Compensation Table, filed March 27, 2026.

Salary
$1.1M
Stock Awards
$5.4M
Option Awards
$5.4M
Incentives
$2.6M
Other
$37K

Historical Compensation

Jonathan J. Mazelsky total compensation, fiscal years 2023–2025.

Year-by-year total compensation
Fiscal YearSalaryTotal Compensation
2025$1,150,000$14,580,122
2024$1,121,154$13,007,051
2023$1,000,000$11,519,309

Named Executive Officers

Source information

Company
Idexx Laboratories Inc
Ticker
IDXX · NASDAQ
Filing type
DEF 14A
Fiscal year
2025
Filing date
March 27, 2026
SEC accession number
0000874716-26-000064

Source: U.S. Securities and Exchange Commission, DEF 14A Summary Compensation Table. View SEC filing

Related Companies